Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 9/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | LDHB | P07195 | 1/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807445 | 0.89 | GABRP (0.53) | CSNK2A1PLK1PLK3PPARARARB | |
| SCHEMBL2808363 | 0.88 | PLK1 (0.56) | PLK1PLK3PPARARARB | |
| SCHEMBL7774557 | 0.87 | CSNK2A1 (0.50) | CSNK2A1PLK1PLK3PPARAMEN1 | |
| SCHEMBL1549076 | 0.86 | CSNK2A1 (0.53) | CSNK2A1PLK1MCL1MEN1KMT2A | |
| SCHEMBL27906431 | 0.86 | PLK1 (0.58) | PLK1PLK3MCL1PPARARARB | |
| SCHEMBL27889924 | 0.86 | PLK1 (0.58) | PLK1PLK3MCL1PPARARARB | |
| SCHEMBL27889926 | 0.86 | PLK1 (0.58) | PLK1PLK3MCL1PPARARARB | |
| SCHEMBL28807894 | 0.86 | PLK1 (0.58) | PLK1PLK3MCL1PPARARARB | |
| SCHEMBL2811080 | 0.86 | PLK1 (0.58) | PLK1PLK3MCL1PPARARARB | |
| SCHEMBL9342043 | 0.86 | PLK1 (0.58) | PLK1PLK3MCL1PPARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569195-B2 | Internal and external donor compounds for olefin polymerization catalysts II | BASF CORPORATION (US) | 2013-10-29 | — | — | US | claimed |
| US-20100068439-A1 | POLYESTER COMPOSITION WITH IMPROVED GAS BARRIER PROPERTIES AND ARTICLES THEREOF | INVISTA North aAmerica S.ar.I (US) | 2010-03-18 | — | — | US | claimed |
| WO-2008095071-A1 | POLYESTER COMPOSITION WITH IMPROVED GAS BARRIER PROPERTIES AND ARTICLES THEREOF | INVISTA TECHNOLOGIES S.AR.L. (CH) | 2008-08-07 | — | — | WO | claimed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
| EP-3260920-A1 | TONER COMPOSITIONS WITH ANTIPLASTICIZERS | Xerox Corporation (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9684257-B1 | Toner compositions with antiplasticizers | XEROX CORPORATION (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2782938-B1 | HIGH ACTIVITY CATALYST FOR OLEFIN POLYMERIZATION | BASF CORP (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100068439-A1 | POLYESTER COMPOSITION WITH IMPROVED GAS BARRIER PROPERTIES AND ARTICLES THEREOF | INVISTA North aAmerica S.ar.I (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008095071-A1 | POLYESTER COMPOSITION WITH IMPROVED GAS BARRIER PROPERTIES AND ARTICLES THEREOF | INVISTA TECHNOLOGIES S.AR.L. (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CSNK2A1 1203/4885PLK1 4432/4885LDHA 3745/4885 |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CSNK2A1 663/4885PLK1 4139/4885LDHA 3753/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CSNK2A1 663/4885PLK1 4139/4885LDHA 3753/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CSNK2A1 1176/4885PLK1 4410/4885LDHA 3590/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CSNK2A1 1348/4885PLK1 4022/4885LDHA 3960/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | CSNK2A1 1321/4885PLK1 4208/4885LDHA 4022/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CSNK2A1 663/4885PLK1 4139/4885LDHA 3753/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | CSNK2A1 1294/4885PLK1 4692/4885LDHA 3547/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CSNK2A1 682/4885PLK1 3397/4885LDHA 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.